Buscar en
Revista Española de Reumatología
Toda la web
Inicio Revista Española de Reumatología HLA-B27 and spondyloarthropathies
Información de la revista
Vol. 28. Núm. 10.
Páginas 405-407 (Diciembre 2001)
Descargar PDF
Más opciones de artículo
Vol. 28. Núm. 10.
Páginas 405-407 (Diciembre 2001)
Acceso a texto completo
HLA-B27 and spondyloarthropathies
Muhammad Asim Khana
a Professor of Medicine. Case Western Reserve University. MetroHealth Medical Center. Cleveland. USA.
Información del artículo
Texto completo

Ankylosing spondylitis (AS) and related spondyloarthropathies (SpA) are more common than RA in many countries. Enthesitis and subchondral inflammation is their pathologic hallmark, and the cartilage destruction seems to start from "inside out" (subchondral & enthesial bone) more than from "outside in" (synovium). The proteoglycans (aggrecan and versican) that aggregate with link protein and hyaluronan, are under study as possible auto-antigen candidates.

The recurrence risk ratios (lamda values) among a set of monozygotic twins, siblings, and offspring indicate that AS results from multiple predisposing factors, both genetic and environmental. The environmental trigger for AS is still unknown, but is likely to be quite ubiquitous. There are expected to be close to five predisposing genes in AS and those have multiplicative interactions. All siblings are not at an equal risk for developing AS because the first born are at a significantly higher risk than others. Moreover, the mothers of AS patients are significantly younger at the time of their first delivery as compared with the mothers of healthy controls.

One of the disease predisposing genes is HLA-B27 itself, but how it predisposes to AS is still unknown despite 28 years of research. Whole genome-wide screenings in AS families indicate that MHC (HLA) region on chromosome 6p encodes the greatest component of susceptibility with an overall LOD score of 15.6, and the strongest non-MHC linkage lies on chromosome16q (LOD score of 4.7). One of the putative genes for psoriasis (PSORS1) is located somewhere in a 60 kb region close to HLA-C locus. This region contains three pseudogenes, and it is speculated that PSORS1 could possibly turn out to be a promoter or a long range acting enhancer sequence affecting gene regulation or expression (e.g., of the nearby gene for corneodesmosin).

A specific susceptibility gene (NOD2) for Crohn's disease has been located on chromosome 16q. The encoded NOD2 protein activates nuclear factor (NF)kappaB in response to bacterial lipopolysaccharide (LPS). A frameshift mutation in the NOD2 gene, caused by a cytosine insertion, results in a mutant-type NOD2 that does not activates NFkappaB. This provides a link between a defective innate immune response to bacterial components (LPS) and Crohn's disease.

A recently proposed novel hypothesis suggests that HLA-B27 misfolding in the endoplasmic reticulum (ER) plays a role in the pathogenesis of AS and related SpA through an ER "unfolded-protein response". This can lead to changes in gene expression profiles and subsequent signaling events to alter the cell behavior involving stress signaling and/or heavy chain (HC) dimer formation. Preliminary evidence in favor of the possibility of in vivo occurrence of "unfolded protein response" has been reported in the synovial fluid mononuclear cells (SFMC) of SpA patients. These cells showed higher expression of three genes encoding proteasome subunits that are known to be induced during an ER unfolded protein response. One of the expressed genes was BiP, commonly accepted as a gold standard for measuring unfolded protein response. HLA-B27 forms both folded and unfolded/misfolded dimers, and tapasin reduces the accumulation of unfolded/misfolded dimers. In vitro studies of HLA assembly in culture cell lines indicate that an intact peptide-loading mechanism in the ER is necessary for the formation of folded HC dimers.

HLA-B27 seems to have had an unusual cell biology as compared to most other HLA class I molecules [19, 122 - 124]; e.g., it may exist in an aberrant form (free heavy chains forming stable homodimers lacking beta(2)-microglobulin), and studies are underway to investigate if there is any recognition of such aberrant forms of HLA-B27 by antibodies, T lymphocytes, or natural killer cells [19, 123]. High level of surface expression of free heavy chains on monocytes of AS patients, and also presence of such monocytes in the synovium of a hip joint of an AS patient have been reported. HLA-B27 has a tendency to fold slowly or misfold as a consequence of its unique B pocket and the presence in the B pocket of the Cys67 residue that leads to the formation of aberrant disulfide-linked HC complexes.

HLA-B27 encompasses 25 different alleles that encode 23 subtypes: HLA-B*2701 to B*2723, that have evolved from the most widespread subtype, B*2705. These subtypes differ from each other mostly in their exons 2 and 3, which encode the alpha 1 and alpha 2 domains of the B27 molecule, respectively. Occurrence of AS or related SpA has thus far been documented in subjects possessing any one of the first ten (B*2701 to B*2710) subtypes studied, but B*2706 in Southeast Asia and B*2709 in the Italian island population of Sardinia seem not to be associated with AS. The 13 most recent subtypes (B*2711 to B*2723) have not yet been studied for disease association, but disease occurrence has been observed in one or more patients with B*2713, B*2716, and B*2719.

One of the strongest reasons to study the HLA-B27 subtypes is to learn the effects of the sequence variations on the peptide-binding specificity of the molecule; among these peptides may be the putative arthritogenic peptide(s). These studies would be expected to provide clues as to the mechanism of disease association with HLA-B27. One needs to also know whether certain subtypes show any preferential association with some of the clinical features or forms of these diseases among the various ethnic/racial populations and geographic regions of the world. It would be of interest to study protein folding of the two rare subtypes of HLA-B27 ­B*2718 and B*2723­ because they do not have the Cys67 residue in their B pockets, unlike all the others.

HLA-B27 is one of the best HLA class I molecules to have for anti-viral defense. For example, the relative risk (RR) of progression of HIV infection to AIDS is lower for someone possessing HLA-B27 (RR = 0.33 [95% CI = 0.16-0.70]) than HLA-B35 (RR = 2.8 [1.7-4.0]) or the HLA phenotype A1, B8, DR3 (RR = 2.5 [1.8-3.7]). Viruses exploit different strategies to escape immune surveillance, including mutations in epitopes recognized by CTL. For example, in the immuno-dominant decamer (aa263-272) peptide (KRWIILGLNK) from HIV p24 gag protein, a substitution of Arginine (R) at residue 264 by Lysine (K) or Glycine (G) results in poor binding to HLA-B27of the resultant epitope. This is one of the documented mechanisms of the HIV "immune escape". The R264K substitution was detected in 4 of 5 HLA-B27(+) patients infected with HIV-1 virus, and R264G substitution in the other, and these coincided with HIV disease progression.

TNF blockading therapy for patients unresponsive to conventional treatment results in quick therapeutic response & significant improvement of both axial and peripheral arthritis as well as enthesitis in approximately 80% of the patients. Methotrexate (MTX) has been used for persistent severe disease, especially involving peripheral joints, but its use in AS is based on anecdotal evidence & uncontrolled studies. The first placebo controlled double blind study found no significant benefit from MTX in AS, even in the peripheral arthritis subgroup. Cyclosporine has not studied in SpA but there is a case report of an AS patient with peripheral arthritis unresponsive to conventional therapy who responded to treatment with cyclosporin. The other (novel) therapies under study include pamidronate, a bisphosphonate given by IV infusion, thalidomide and Anakirna (anti-IL-1 receptor antagonist) has just been approved for RA but has not been studied in SpA.


Bakker C, Hidding A, van der Linden S, van Doorslaer E. Cost effectiveness of group physical therapy compared to individualized therapy for ankylosing spondylitis. A randomized controlled trial. J Rheumatol 1994; 21: 264-268.

Banares A, Hernández-García C, Fernández-Gutiérrez B, Jover JA. Eye involvement in the spondyloarthropathies. Rheum Dis Clin North Am 1998; 24: 771-784.

Braun J, Bollow M, Sieper J. Radiologic diagnosis and pathology of the spondyloarthropathies. Rheum Dis Clin North Am 1998; 24 (4): 697-735.

Braun J, de Keyser F, Brandt J, Mielants H, Sieper J, Veys E. New treatment options in spondyloarthropathies: increasing evidence for significant efficacy of anti-TNF therapy. Curr Opin Rhaumatol 2001; 13: 245-249.

Braun J, Khan MA, Sieper J. Enthesitis and ankylosis in spondyloarthropathy: what is the target of the immune response? Ann Rheum Dis 2000; 59: 985-994.

Braun J, Sieper J. Anti-TNF-alpha: a new dimension in the pharmacotherapy of the spondyloarthropathies. Ann Rheum Dis 2000; 59: 404-407.

Breban M, Gombert B, Amor B, Dougados M. Efficacy of thalidomide in the treatment of refractory ankylosing spondylitis. Arthritis Rheum 1999; 42: 580-581.

Calin A, Taurog J, editors. Spondylarthritides. Oxford: Oxford University Press, 1998; 1-347.

Cassidy JT, Petty RE, editors. Textbook of Pediatric Rheumatology. 4th ed. Philadelphia: W. B. Saunders, 2001.

Colbert RA. HLA-B27 Misfolding and Spondyloarthropathies: Not So Groovy After All? [Editorial]. J Rheumatol 2000; 27: 1107-1109.

Collantes E, Veroz R, Escudero A, Muñoz E, Muñoz MC, Cisnal A, Pérez V. Can some cases of 'possible' spondyloarthropathy be classified as 'definite' or 'undifferentiated' spondyloarthropathy? Value of criteria for spondyloarthropathies. Spanish Spondyloarthropathy Study Group. Joint Bone Spine 2000; 67: 516-520.

D'Amato M, Fiorillo MT, Galeazzi M, Martinetti M, Amoroso A, Sorrentino R. Frequency of the new HLA-B*2709 allele in ankylosing spondylitis patients and healthy individuals. Dis Markers 1995; 12: 215-217.

De Vlam K, Mielants H, Cuvelier C, De Keyser F, Veys EM, De Vos M. Spondyloarthropathy is underestimated in inflammatory bowel disease: prevalence and HLA association. J Rheumatol 2000; 27: 2860-2865.

Dougados M, Revel M, Khan MA. Management of spondyloarthropathy. In: van de Putte LBA, Williams HJ, van Riel P, Furst DE, editors. Therapy of Systemic Rheumatic Disorders. New York: Marcel Dekker, 1998; 375-406.

Edward Ball, Khan MA. The polymorphism of HLA-B27. Bone Joint Spine 2001; 68: 378-382.

Erturk M, Alaca R, Tosun E, Duruoz MT. Evaluation of the Amor and ESSG classification criteria for spondylarthropathies in a Turkish population. Rev Rhum Engl Ed 1997; 64: 293-300.

François RJ, Braun J, Khan MA. Entheses and enthesitis: a histopathological review and relevance to spondyloarthropathies. Curr Opin Rheumatol 2001; 13: 255-264.

Granfors K, Märker-Hermann E, De Keyser P, Khan MA, Veys EM, Yu DT. The cutting edge of spondyloarthropathy research in the millenium. Arthritis Rheum (in press).

Hampe J, Cuthbert A, Croucher PJ, Mirza MM, Mascheretti S, Fisher S et al. Association between insertion mutation in NOD2 gene and Crohn's disease in German and British populations. Lancet 2001; 357: 1902-1904.

Hohler T, Marker Hermann E. Psoriatic arthritis: Clinical aspects, genetics, and the role of T cells. Curr Opin Rheumatol 2001; 13: 273-279.

Hugot JP, Chamaillard M, Zouali H, Lesage S, Cezard JP, Belaiche J et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature 2001; 411: 599-603.

Khan MA. Update on spondyloarthropathies. Ann Intern Med 2002 (in press).

Khan MA. Ankylosing spondylitis. In: Rakel RE, editor. Conn's Current Therapy. 1999 ed. Philadelphia: WB Saunders Co., 1999; 994-996.

Kraag G, Stokes B, Groh J, Helewa A, Goldsmith C. The effects of comprehensive home physiotherapy and supervision on patients with ankylosing spondylitis: a randomized controlled trial. J Rheumatol 1990; 17: 228-233.

Lauhio A, Leirisalo-Repo M, Lahdevirta J, Saikku P, Repo H. Double-blind, placebo-controlled study of three-month treatment with lymecycline in reactive arthritis, with special reference to Chlamydia arthritis. Arthritis Rheum 1991; 34: 6-14.

Laval SH, Timms A, Edwards S, Bradbury L, Brophy S, Milicic A et al. Whole-genome screening in ankylosing spondylitis: Evidence of non-MHC genetic-susceptibility loci. Am J Hum Genet 2001; 68: 916-926.

Lorenz HM. TNF inhibitors in the treatment of arthritis. Curr Opin Investig Drugs 2000; 1: 188-193.

Mader R. Atypical clinical presentation of ankylosing spondylitis. Semin Arthritis Rheum 1999; 29: 191-196.

Maksymowych W. Ankylosing spondylitis: at the interface of bone and cartilage. J Rheumatol 1999; 27: 2295-2301.

Maksymowych WP, Lambert R, Jhangri GS, Leclercq S, Chiu P, Wong B et al. Clinical and radiological amelioration of refractory peripheral spondyloarthritis by pulse intravenous pamidronate therapy. J Rheumatol 2001 28 (1): 144-155.

Mease PJ, Goffe BS, Metz J, VanderStoep A, Finck B, Burge DJ. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomized trial. Lancet 2000; 356: 385-390.

Mijiyawa M, Oniankitan O, Khan MA. Spondyloarthropathies in sub-Saharan Africa. Curr Opin Rheumatol 2000; 12: 263-268.

Nair RP, Stuart P, Henseler T, et al. Localization of psoriasis-susceptibility locus PSORS1 to a 60-kb interval telomeric to HLA-C. Am J Hum Genet 2000; 66: 1833-1844.

Nasution AR, Mardjuadi A, Kunmartini S, Suryadhana NG, Setyohadi B, Sudarsono D, et al. HLA-B27 subtypes positively and negatively associated with spondyloarthropathy. J Rheumatol 1997; 24: 1111-1114.

Ogura Y, Bonen DK, Inohara N, Nicolae DL, Chen FF, Ramos R et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature 2000; 411: 603-606.

Olivieri I, Salvarani C, Cantini F, Ciancio G, Padula A. Ankylosing spondylitis and unidifferentiated spondyloarthropathies: A clinical review and description of a disease subset with older age of onset. Curr Opin Rheumatol 2001; 13: 280-284.

Pato E, Banares A, Jover JA, Fernández-Gutiérrez B, Godoy F, Morado C et al. Undiagnosed spondyloarthropathy in patients presenting with anterior uveitis. J Rheumatol 2000; 27: 2198-2202.

Queiro R, Maiz O, Intxausti J, De Dios JR, Belzunegui J, González C et al. Subclinical sacroiliitis in inflammatory bowel disease: a clinical and follow-up study. Clin Rheumatol 2000; 19: 445-449.

Reveille JD, Ball EJ, Khan MA. HLA-B27 and genetic predisposing factors in spondyloarthropathies. Curr Opin Rheumatol 2001; 13: 265-272.

Poole AR. The Histopathology of Ankylosing Spondylitis: Are There Unifying Hypotheses? Am J Med Sci 1998; 316: 228-233.

Roldán CA, Chávez J, Wiest PW, Qualls CR, Crawford MH. Aortic root disease and valve disease associated with ankylosing spondylitis. J Am Coll Cardiol 1998; 32: 1397-1404.

Roychaudhry B, Bintley-Bagot S, Hunt J, Tunn EJ. Methotrexate in severe ankylosing spondylitis: a randomized placebo controlled, double-blind observer study [Abstract]. Rheumatology 2001; 40 (Suppl. 1): 43.

Sieper J, Fendler C, Laitko S, Sorensen H, Gripenberg-Lerche C, Hiepe F et al. No benefit of long-term ciprofloxacin treatment in patients with reactive arthritis and undifferentiated oligoarthritis: a three-month, multicenter, double-blind, randomized, placebo-controlled study. Arthritis Rheum 1999; 42: 1386-1396.

Van den Bosch F, Kruithof E, Baeten D, De Keyser F, Mielants H, Veys EM et al. Effects of a loading regimen of three infusions of chimeric monoclonal antibody to tumor necrosis factor alpha (infliximab) in spondyloarthropathy: an open pilot study. Ann Rheum Dis 2000; 59: 428-433.

Wakefield D, McCluskey P, Verma M, Aziz K, Gatus B, Carr G. Ciprofloxacin does not influence the course or relapse rate of reactive arthritis. Arthritis Rheum 1999; 42: 1894-1897.

Wendling D, Toussirot E, Michel F. Thalidomide: a comeback? Joint Bone Spine 2001; 67: 259-261.

Zabraniecki L, Fournié B. TNF alpha inhibition in psoriatic arthritis: cause for hope. Joint Bone Spine 2001; 68: 106-108.

Opciones de artículo
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos